Kailun Fei

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences · ORCID：0000-0002-6813-9362

发表论文 54 篇 · 总被引 1402 次 · h-index 18

代表论文

• Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity (2023 · Cell Reports Medicine · 被引 53)
• CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations (2023 · Journal of Thoracic Oncology · 被引 20)
• Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment (2023 · Thoracic Cancer · 被引 18)
• Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy (2023 · Cell Reports Methods · 被引 11)
• Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial (2025 · The Lancet Respiratory Medicine · 被引 10)
• Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients (2025 · Signal Transduction and Targeted Therapy · 被引 9)